Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics DOI Creative Commons
Abdurraouf Mokhtar Mahmoud,

Clara Deambrogi

Applied Biosciences, Journal Year: 2025, Volume and Issue: 4(1), P. 16 - 16

Published: March 5, 2025

Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, pose significant therapeutic challenges due to their heterogeneity high relapse rates. Nanotechnology has emerged as a promising avenue for precision drug delivery in these allowing enhanced concentration at tumor sites reducing systemic toxicity. Recent developments nanocarriers—such liposomes, polymeric nanoparticles, inorganic nanoparticles—have enabled targeted approaches, utilizing molecular markers specific malignant cells increase efficacy while minimizing adverse effects. Evidence from preclinical clinical studies underscores the potential of nanotechnology improve patient outcomes by facilitating controlled release, improved bioavailability, reduced However, translating advancements into practice requires further research validate safety efficacy. This review provides comprehensive analysis latest innovations hematologic addressing current achievements future directions integrating approaches Clinical Hemato-Oncology.

Language: Английский

Biomolecule-based engineered nanoparticles for Cancer Theranostics DOI

Narayanan Parthasarathy,

Ramar Thangam, Babu Rithisa

et al.

Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 530, P. 216489 - 216489

Published: Feb. 3, 2025

Language: Английский

Citations

1
Acid-Unlocked Two-Layer Ca-Loaded Nanoplatform to Interfere With Mitochondria for Synergistic Tumor Therapy DOI Creative Commons
Yilu Zheng, Gareth R. Williams,

Ran Hu

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 1899 - 1920

Published: Feb. 1, 2025

Background: The development of selective formulations able to target and kill tumor cells without the application external energy has shown great promise for anti-tumor therapy. Methods: Here, we report a "nanobomb" that explosively increases Ca content within cells. It can selectively release 2+ generate H 2 O in microenvironment (TME) by acid-triggered degradation two-layer protective shell (ie, unlocking "double-lock"). This material, termed CaO @ZIF8:CUR@PAA, comprises core coated with ZIF-8 framework, which was then loaded curcumin (CUR) again polyacrylic acid (PAA). Results: Under slightly acidic conditions TME, PAA (first lock) breaks down first exposing @ZIF8 CUR inside cell. Then, ZIF8 (second is degraded response deposit , . promote from endoplasmic reticulum cytoplasm, inhibit outflow accumulates large amount intracellularly together exogenous (calcium storms). powerful calcium storm causes mitochondrial dysfunction. presence further oxidative damage cell membranes mitochondria where intracellular ROS production far exceeds clearance. @ZIF8:CUR@PAA NPs induce S cycle arrest apoptosis multiplication growth. Oxidative damage-triggered immunogenic death (ICD) turn leads polarization macrophages M1 phenotype, inducing inhibiting proliferation metastasis. Discussion: two-step nanoplatform therapeutic modality combines damage. mode triggers leading ICD material induces blockade during treatment proliferation. Robust vitro vivo data demonstrate efficacy this approach as an anticancer platform, paving way nanomaterials immune-triggered cancer Highlights: - A new accumulation plays role activate antitumor immunity.- Double-locked structure slows premature decomposition .- platform allows accumulate cells.- dysfunction, apoptosis, macrophage polarization.- Potent effects are seen both vivo. Keywords: Calcium ion load, controlled-release nanomaterials, shell, pH responsive drug release, reactive oxygen species, anti-cancer

Language: Английский

Citations

1
Polysaccharides as therapeutic vehicles in pancreatic cancer DOI
Seema Kumari, Sujatha Peela,

Ganji Purnachandra Nagaraju

et al.

Drug Discovery Today, Journal Year: 2025, Volume and Issue: unknown, P. 104320 - 104320

Published: Feb. 1, 2025

Language: Английский

Citations

0
A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia DOI Creative Commons
Yaoyao Wang,

Xiancong Yang,

Yalin Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 10, 2025

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Traditional chemotherapy methods not only bring serious side effects, but also lead to high recurrence rate and drug resistance in some patients. However, as an emerging therapeutic strategy, immunotherapy has shown great potential the field of AML treatment recent years. At present, common for include monoclonal antibodies, CAR-T cell therapy, immune checkpoint inhibitors. With deepening research technological progress, especially application nanotechnology medicine, new expected become one important means acute future.

Language: Английский

Citations

0
From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment DOI
Qi Wang, Phil‐Sun Oh, Hwan‐Jeong Jeong

et al.

Photochemistry and Photobiology, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract Photobiomodulation (PBM) is a non‐invasive therapeutic technique that regulates biological processes using primarily low‐power lasers or light‐emitting diodes (LEDs) to achieve effects. Its application has expanded significantly, particularly in the field of cancer therapy. This review provides comprehensive overview PBM, elucidating its underlying mechanisms action and potential applications It highlights benefits PBM reducing side effects treatments such as acute oral mucositis, radiation dermatitis, lymphedema, neuropathic pain, enteropathy. Furthermore, ability inhibit cell proliferation induce apoptosis, discusses safety concerns clinical applications, presenting existing research emphasizes significant therapy was summarized. may offer promising new options for managing mitigating associated with conventional therapies.

Language: Английский

Citations

0
Biomaterials Mimicking Mechanobiology: A Specific Design for a Specific Biological Application DOI Open Access

Leonardo Donati,

Maria Luisa Valicenti,

Samuele Giannoni

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10386 - 10386

Published: Sept. 26, 2024

Mechanosensing and mechanotransduction pathways between the Extracellular Matrix (ECM) cells form essential crosstalk that regulates cell homeostasis, tissue development, morphology, maintenance, function. Understanding these mechanisms involves creating an appropriate support elicits signals to guide cellular functions. In this context, polymers can serve as ideal molecules for producing biomaterials designed mimic characteristics of ECM, thereby triggering responsive closely resemble those induced by a natural physiological system. The generated specific stimuli depend on different or synthetic origins polymers, chemical composition, assembly structure, physical surface properties biomaterials. This review discusses most widely used their customization develop with tailored properties. It examines how biomaterials-based be harnessed replicate functions biological cells, making them suitable biomedical biotechnological applications.

Language: Английский

Citations

3
Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics DOI Creative Commons
Abdurraouf Mokhtar Mahmoud,

Clara Deambrogi

Applied Biosciences, Journal Year: 2025, Volume and Issue: 4(1), P. 16 - 16

Published: March 5, 2025

Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, pose significant therapeutic challenges due to their heterogeneity high relapse rates. Nanotechnology has emerged as a promising avenue for precision drug delivery in these allowing enhanced concentration at tumor sites reducing systemic toxicity. Recent developments nanocarriers—such liposomes, polymeric nanoparticles, inorganic nanoparticles—have enabled targeted approaches, utilizing molecular markers specific malignant cells increase efficacy while minimizing adverse effects. Evidence from preclinical clinical studies underscores the potential of nanotechnology improve patient outcomes by facilitating controlled release, improved bioavailability, reduced However, translating advancements into practice requires further research validate safety efficacy. This review provides comprehensive analysis latest innovations hematologic addressing current achievements future directions integrating approaches Clinical Hemato-Oncology.

Language: Английский

Citations

0